EP2086317A4 - Nicotine formulations, kits and systems and methods for their use - Google Patents

Nicotine formulations, kits and systems and methods for their use

Info

Publication number
EP2086317A4
EP2086317A4 EP07867591A EP07867591A EP2086317A4 EP 2086317 A4 EP2086317 A4 EP 2086317A4 EP 07867591 A EP07867591 A EP 07867591A EP 07867591 A EP07867591 A EP 07867591A EP 2086317 A4 EP2086317 A4 EP 2086317A4
Authority
EP
European Patent Office
Prior art keywords
kits
systems
methods
nicotine formulations
nicotine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07867591A
Other languages
German (de)
French (fr)
Other versions
EP2086317A2 (en
Inventor
Igor Gonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aradigm Corp
Original Assignee
Aradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/931,867 external-priority patent/US20080138398A1/en
Priority claimed from US11/931,921 external-priority patent/US20080138399A1/en
Priority claimed from US11/932,402 external-priority patent/US20080138294A1/en
Priority claimed from US11/932,437 external-priority patent/US8256433B2/en
Application filed by Aradigm Corp filed Critical Aradigm Corp
Publication of EP2086317A2 publication Critical patent/EP2086317A2/en
Publication of EP2086317A4 publication Critical patent/EP2086317A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
EP07867591A 2006-12-01 2007-11-30 Nicotine formulations, kits and systems and methods for their use Withdrawn EP2086317A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US86823806P 2006-12-01 2006-12-01
US91104407P 2007-04-10 2007-04-10
US91318507P 2007-04-20 2007-04-20
US91651007P 2007-05-07 2007-05-07
US91719007P 2007-05-10 2007-05-10
US98207007P 2007-10-23 2007-10-23
US11/931,867 US20080138398A1 (en) 1999-07-16 2007-10-31 Dual release nicotine formulations, and systems and methods for their use
US11/931,921 US20080138399A1 (en) 1999-07-16 2007-10-31 Dual release nicotine formulations, and systems and methods for their use
US11/932,402 US20080138294A1 (en) 1999-07-16 2007-10-31 Systems and methods for effecting cessation of tobacco use
US11/932,437 US8256433B2 (en) 1999-07-16 2007-10-31 Systems and methods for effecting cessation of tobacco use
PCT/US2007/024636 WO2008069970A2 (en) 2006-12-01 2007-11-30 Nicotine formulations, kits and systems and methods for their use

Publications (2)

Publication Number Publication Date
EP2086317A2 EP2086317A2 (en) 2009-08-12
EP2086317A4 true EP2086317A4 (en) 2010-03-03

Family

ID=39492806

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07867591A Withdrawn EP2086317A4 (en) 2006-12-01 2007-11-30 Nicotine formulations, kits and systems and methods for their use
EP07867592A Withdrawn EP2086527A4 (en) 2006-12-01 2007-11-30 Systems for effecting cessation of tobacco use

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07867592A Withdrawn EP2086527A4 (en) 2006-12-01 2007-11-30 Systems for effecting cessation of tobacco use

Country Status (2)

Country Link
EP (2) EP2086317A4 (en)
WO (2) WO2008069972A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP2012517402A (en) * 2009-02-11 2012-08-02 ヘグルンド、エー．エス． Composition for buccal absorption of nicotine for smoking cessation
WO2011023796A1 (en) * 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
TWI484958B (en) * 2011-05-19 2015-05-21 Heglund A S A composition for buccal absorption of nicotine for the purpose of smoking cessation
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
RU2541312C2 (en) * 2011-08-31 2015-02-10 Александр Васильевич Иващенко Pharmaceutical composition, method for preparing and device for using it
US10556011B2 (en) 2011-12-02 2020-02-11 Joshua D. Levine Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
WO2015042412A1 (en) 2013-09-20 2015-03-26 E-Nicotine Technology. Inc. Devices and methods for modifying delivery devices
JP2018511355A (en) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug delivery method and system
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US20170071248A1 (en) * 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
RU2770039C2 (en) * 2017-03-07 2022-04-14 Филип Моррис Продактс С.А. Inhaled nicotine-based compositions and methods for production and application thereof
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Drug delivery methods and systems
GB201817863D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
WO2001005459A1 (en) * 1999-07-16 2001-01-25 Aradigm Corporation System for effecting smoke cessation
WO2003097146A1 (en) * 2002-05-15 2003-11-27 Aradigm Corporation System for effecting smoke cessation
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
ES2097443T3 (en) * 1992-02-20 1997-04-01 Wielligh Johannes Louw Kot Von PRODUCT TO HELP SMOKERS TO ABANDON THE HABIT.
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US20070100000A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of providing neuroprotection
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
WO2001005459A1 (en) * 1999-07-16 2001-01-25 Aradigm Corporation System for effecting smoke cessation
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
WO2003097146A1 (en) * 2002-05-15 2003-11-27 Aradigm Corporation System for effecting smoke cessation

Also Published As

Publication number Publication date
EP2086317A2 (en) 2009-08-12
EP2086527A4 (en) 2010-03-03
WO2008069972A2 (en) 2008-06-12
WO2008069970A2 (en) 2008-06-12
EP2086527A2 (en) 2009-08-12
WO2008069970A3 (en) 2008-10-16
WO2008069972A3 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
EP2086317A4 (en) Nicotine formulations, kits and systems and methods for their use
GB2449806B (en) Multi-zone, single trip well completion system and methods of use
TWI347760B (en) Methods, apparatus, and system for venue-cast
AU2007275047A8 (en) Compositions and methods for vaccinating against HSV-2
GB2443930B (en) Amplifier
EP1986702A4 (en) Hyperpolarization methods, systems and compositions
EP1853696A4 (en) Electro-blotting devices, systems, and kits, and methods for their use
EP1850755A4 (en) Devices, systems and methods for plaque type determination
IL201303A0 (en) Compositions, devices, systems, and methods for using a nanopore
EP2151500A4 (en) Branched -glucan, -glucosyltransferase producing the same, method for producing the same and use thereof
EP2005625A4 (en) Methods, systems, and apparatus for multi-purpose metering
ZA200901677B (en) Disinfectant systems and methods
GB0601143D0 (en) Uses, methods and compositions
GB0616111D0 (en) Agents, methods and uses
PL1988090T3 (en) Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof
HUP0500921A2 (en) Tetrazole derivatives, process for their preparation and their use
IL196851A0 (en) Systems and methods for using an http-aware client agent
EP2191431A4 (en) Methods and systems for trading options and other derivatives
GB0719592D0 (en) Compound, use and method
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
TWI366746B (en) Lithography system and lithography method using the same
HK1120837A1 (en) Elastic interlining, method for its manufacture and use
GB0620930D0 (en) Composition and method for use thereof
GB2453860B (en) Ionizing-radiation-responsive compositions,methods and systems
GB0607562D0 (en) Method, composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090529

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GONDA, IGOR

A4 Supplementary search report drawn up and despatched

Effective date: 20100203

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/135 20060101AFI20100128BHEP

Ipc: A61P 25/34 20060101ALI20100128BHEP

Ipc: A61K 31/465 20060101ALI20100128BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110708